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Stem cells have huge potential for regenerative medicine. Adult stem cell (HSC)-based therapies have been pro-
ved to be safe and efficient for several decades, and adult MSC therapies are showing efficacy in some experi-
ments while in other trials mixed results are obtained such as only short lived effects due to poor cellular retention
or other reasons that have to be further tested. Although iPSCsmight suggest a great hope for the stem cell therapy,
still there are important safety issues to be considered before these cells are marketed for clinical trials. However,
the advanced potential to generate stem cell lines, matched to a particular patient, and to perform homologous
gene correction or targeted transgene insertion into a safe dock site in the genome prior to further expansion and
differentiation offer great prospects for future regenerative medicine. Furthermore, the development of the recom-
binant adeno-associated virus (rAAV) technology and the use of the Zinc Finger Nuclease (ZFN) technology are
promoting the homologous recombination as a best possible tool for stem cell-based gene therapy.
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Introduction. Stem cell gene therapy is a novel thera-
peutic branch of modern medicine. Gene therapy is still
highly experimental, but has the potential to become an
important course of therapy. In principle, it allows the
transfer of genetic information into patient tissues and
organs. Subsequently, the diseased genes can be eradi-
cated or their normal functions restored. Moreover, the
procedure ensures the addition of novel functions to cells,
such as the production of immune systemmediator pro-
teins that facilitate to fight cancer and other diseases.
In the beginning, monogenic inherited diseases,
such as cystic fibrosis, were considered prime targets for
gene therapy. For example, in the pioneering study on
the correction of adenosine deaminase deficiency, a lym-
phocyte associated severe combined immunodeficien-
cy (SCID), was attempted for gene therapy trial [1],
although no modification of immune function was ob-
served. The first successful gene therapy clinical trial for
amonogenic disorder is related to another type of SCID,
caused by mutation of the X chromosome-linked lym-
phocyte growth factor receptor [2].
While the positive therapeutic outcomewas celebra-
ted as a step forward for gene therapy, a serious nega-
tive aspect became evident subsequently. By February
2005, three children out of seventeen, who had been suc-
cessfully treated for X linked SCID, developed leuke-
mia because the vector inserted near an oncogene unin-
tentionally caused its expression in the genetically-en-
gineered lymphocyte target cells [3]. On a more positi-
ve note, a small number of patients with adenosine de-
aminase deficient SCID have been successfully treated
by gene therapy without any adverse side effects [4].
Another emerging approach to treat disorders re-
quiring the replacement of injured or dying cells is to
substitute those cells with healthy ones generated from
stem cells, which have the potential to differentiate into
multiple mature cell types. Recent discoveries, based on
embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs), elevate the hope for future regene-
rative medicine application, with one human ESC-ba-
sed therapy already being tested in a first-in-man phase I
clinical trial. In spite of the great potential, there are te-
chnical challenges to be overcome before pscs can be
applied to clinical practice in a broader mode.
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Progression of gene therapy. Gene therapy can be
performed either by direct transfer of genes into the pa-
tient or by using living cells as vehicles to transport the
genes of interest. Both modes have certain advantages
and disadvantages. Direct gene transfer is particularly
attractive because of its relative simplicity. In this case,
genes are delivered directly into a patient’s tissues or
bloodstream by packaging into liposomes or other biolo-
gical microparticles. Alternately, the genes are packaged
into genetically engineered viruses, such as retroviru-
ses or adenoviruses. Due to biosafety issues, the viruses
are usually transformed so that they are not toxic or in-
fectious, meaning they are replication incompetent. The-
se basic tools of gene therapists have beenwidely optimi-
zed over the past 10 years.
In many cases, direct gene transfer does not allow
very fine control over the therapeutic gene. This is becau-
se the transferred gene either accidentally integrates into
the patient’s chromosomes or persists unintegrated for
a pretty short period of time in the targeted tissue. More-
over, the targeted organ or tissue is not always easily
available for direct application of the therapeutic gene.
On the other hand, the therapeutic genes can be de-
livered using living cells. This procedure is relatively
complex in comparison to direct gene transfer, and can
be divided into three major steps. In the first step, cells
from the patient or other sources are isolated and pro-
pagated in the laboratory. Second, the therapeutic gene
is introduced into these cells, applying methods similar
to those used in direct gene transfer. Ultimately, the
genetically modified cells are returned to the patient.
The use of cells as gene transfer vehicles has certain
advantages. In the laboratory dish, cells can bemanipu-
lated much more precisely than in the body. Some of
the cell types that continue to divide under laboratory
conditions may be expanded significantly before reintro-
duction into the patient.
Moreover, some cell types are able to localize in par-
ticular regions of the human body, such as hematopoie-
tic stem cells, which return to the bone marrow. This
«homing» phenomenon may be useful for applying the
therapeutic gene with regional specificity. A major dis-
advantage, however, is the additional biological comp-
lexity brought into systems by living cells. Isolation of
a specific cell type requires not only extensive know-
ledge of biological markers, but also insight into the
requirements for that cell type to stay alive in vitro and
continue to divide.
Importance of stem cells for gene therapy. Stem
cells can be classified as embryonic or adult, depending
on their origin. The role of adult stem cells is to maintain
an established collection of mature cell types in essen-
tially steady state number over the life span of an orga-
nism. Although adult tissues with a high turnover rate,
such as blood, skin, and intestinal epithelium, are main-
tained by the tissue specific stemcells, stemcells themsel-
ves rarely divide. However, in certain situations, such as
during tissue repair after injury or following transplanta-
tion, stem cells divisionmay becomemore frequent. The
prototypic example of adult stem cells, the hematopoie-
tic stem cell, has already been demonstrated to be of utility
in gene therapy [2, 4]. Although they are relatively rare in
the human body, these cells can be readily isolated from
bonemarrow or after mobilization into peripheral blood.
Specific surface markers allow the identification and en-
richment of the hematopoietic stem cells from a mixed
population of bone marrow or peripheral blood cells.
After in vitromanipulation, these cellsmay be retrans-
planted into patients by injection into the bloodstream,
where they travel automatically to the place in the bone
marrow in which they are functionally active. Hemato-
poietic stem cells that have been explanted, in vitroma-
nipulated, and retransplanted into the same patient (au-
tologous transplantation) or a different patient (alloge-
neic transplantation) retain the ability to contribute to all
mature blood cell types of the recipient for an extended
period of time. Another type of adult bone marrow-de-
rived stem cells with potential use as a vehicle for gene
transfer is the mesenchymal stem cell, which has the
ability to form cartilage, bone, adipose (fat) tissue, and
marrow stroma [5]. Recently, a related stem cell type,
the multipotent adult progenitor cell, has been isolated
from bone marrow that can differentiate into multiple
lineages, including neurons, hepatocytes, endothelial
cells and other cell types [6]. Other adult stem cells ha-
ve been identified, such as those in the central nervous
system and heart, but these are less well characterized
and not as easily accessible [7].
The traditional method to introduce a therapeutic
gene into hematopoietic stem cells from bone marrow
or peripheral blood involves the use of a vector derived
from a certain class of viruses, called a retrovirus. One
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type of retroviral vector was initially employed to show
proof of principle that a foreign gene introduced into bo-
ne marrow cells may be stably maintained for several
months [8]. However, these particular retroviral vectors
were only capable of transferring the therapeutic gene
into actively dividing cells. Since most adult stem cells
divide at a relatively slow rate, efficiency was rather
low. The vectors derived from other types of retrovi-
ruses (lentiviruses) and adenoviruses have the potential
to overcome this limitation, since they target non divi-
ding cells as well.
The major drawback of these methods is that the
therapeutic gene frequently integrates more or less ran-
domly into chromosomes of the target cell. In principle,
this is dangerous, because the gene therapy vector can
potentially modify the activity of neighboring genes
either positively or negatively in close proximity to the
insertion site or even inactivate host genes by integra-
ting into them. These phenomena are referred to as
«insertional mutagenesis». In extreme cases, such as in
the X-linked SCID gene therapy trials, these mutations
contribute to the malignant transformation of the targe-
ted cells, ultimately resulting in cancer.
Another major limitation of using adult stem cells
is that it is relatively difficult to maintain the stem cell
state during ex vivo manipulations. Under current sub-
optimal conditions, adult stem cells tend to lose their
stem cell properties and become more specialized, gi-
ving rise to mature cell types through a process termed
«differentiation». Recent advances in supportive cultu-
re conditions for mouse hematopoietic stem cells may
ultimately facilitate more effective use of human hema-
topoietic stem cells in gene therapy applications [9, 10].
Embryonic stem cells and ethical concerns. Emb-
ryonic stem cells are capable of unlimited self renewal
while maintaining the potential to differentiate into de-
rivatives of all three germ layers. Even after months
and years of growth in the laboratory, they retain the
ability to form any cell type in the body. These proper-
ties reflect their origin from cells of the early embryo at
a stage during which the cellular machinery is geared
toward the rapid expansion and diversification of cell
types. The murine embryonic stem cells were isolated
over 25 years ago and paved the way for the isolation of
nonhuman primate, and finally the human embryonic
stem cells [11–13].
Experiments performed with the human embryonic
stem cells in the last few years indicate that these cells
have the potential to make an important impact on me-
dical science, at least in certain fields. Embryonic stem
cells are, no doubt, the ultimate solution for the success-
ful gene therapy but religious scholars of the whole
world have posed serious ethical concerns on the use of
embryonic stem cell. So, in most parts of the world the
use of embryonic stem cells for research purposes have
been banned.
Gene targeting in human somatic cells by homo-
logous recombination. It is extremely useful to be able
to do gene targeting by homologous recombination in
human somatic cells. In the last few years, two different
strategies have been developed to increase the rate of ge-
ne targeting in human somatic cells: the use of recombi-
nant adeno-associated virus and the stimulation of gene
targeting by DNA double-strand breaks.
Homologous recombination by recombinant ade-
noassociated virus (rAAV). The first indication that
gene targeting in mammalian somatic cells might be
possible at frequencies that could be experimentally
useful came from the work of David Russell and his col-
leagues who used rAAV [14]. rAAV is a single-stran-
ded DNA virus of the parvovirus family that depends
on cells being co-infected with either adenovirus or
herpes virus to be replicated. The normal nucleic acid
structure of AAV consists of the Rep and Cap genes
flanked by inverted terminal repeats (ITR’s).
In rAAV, the Rep and Cap genes are replaced with
an expression cassette including a promoter and a gene
of interest. The recombinant virus is then made in
HEK-293 cells by providing the Rep and Cap protein
products in trans. rAAV is capable of infecting a varie-
ty of cell types and has been studied as a possible vector
for many gene therapy trials, including treatment for
hemophilia B [15, 16]. Once rAAV infects cells it can
be maintained episomally in non-dividing cells or can
integrate randomly into the genome, just like other frag-
ments of DNA. Russell and his colleagues found, how-
ever, that rAAV integrated via homologous recombi-
nation at a much higher frequency than anticipated [14].
The rate of gene targeting by homologous recombi-
nation was directly related to the multiplicity of infec-
tion; that is, the more viruses infected cells, the higher
the rate of gene targeting. Under certain circumstances,
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rAAV can achieve gene targeting rates of 1 % or grea-
ter. The mechanism by which rAAV causes a high rate
of gene targeting is a mystery.
Nonetheless, gene targeting by rAAV continues to be
developed as a technology, and a protocol to streamline
the production of rAAV virus for gene targeting has
been established [17]. There are good reasons to expect
that this technology could be broadly useful for
mammalian geneticists.
Homologous recombination induced by DNA
double-strand breaks (DSBs). The second way to sti-
mulate ge ne targeting in mammalian somatic cells is to
create DNADSBs in the genomic target. Homologous re-
combination is an evolutionarily conserved mechanism
to repair DSBs.
In the normal repair of DSBs by homologous re-
combination, the sister-chromatid, an exact duplicate of
the damaged DNA, serves as the template for homolo-
gous recombination. In this way, homologous recombi-
nation is considered the most accurate form of DSB
repair. If the DSB was repaired by homologous DNA
that was not the sister-chromatid, such as an extra-chro-
mosomal fragment of DNA, it might be possible to
«trick» the cell into undergoing gene targeting. In the
mid-1990’s several groups explored this possibility by
using the I-SceI endonuclease (Sce), which is a yeast
homing endonuclease [18, 19]. Sce differs from stan-
dard restriction endonucleases (which have recognition
sites of 4, 6, or 8 basepairs) by having a recognition site
of 18 basepairs. Due to the long recognition site homing
endonucleases are sometimes referred to as «meganuc-
leases». When Sce is expressed in a vertebrate cell that
has a Sce recognition site (Sce site) integrated into its
genome, Sce will create a DSB at its recognition site
[20]. That is, Sce is active in genomic DNA with its
accompanying chromatin modifications in vertebrate
cells. If Sce could create a DSB in the genome, then
could that DSB serve as a stimulus for gene targeting
by homologous recombination?
To satisfy this question, Sce sites were inserted into
mutated reporter genes that were then integrated into
the genome of different mammalian cells. A plasmid
that expressed Sce and a plasmid that could serve as a
repair template were then introduced into these cells. If
homologous recombination occurred between the re-
pair template and the mutated integrated reporter gene,
then the reporter gene would become functional. The
frequency of such spontaneous gene targeting is appro-
ximately one in a million. The limitation, of course, to
this system, is that the Sce site has to be introduced into
the desired target gene beforehand. Since no mamma-
lian gene has the endogenous Sce site within it, this
posed a potentially severe limitation to the application
of DSB induced gene targeting. To solve this problem,
a method of creating DSBs at specific genomic sites is
needed to be developed. One possible way to create such
DSBs is to redesign meganucleases, such as Sce, for re-
cognizing novel target sites [21].
Zinc finger nucleases create site specific DSBs.
Type IIS restriction endonucleases are enzymes that
bind a specific DNA recognition site but cleave DNA at
a short distance from this site. FokI is an example of
such a restriction enzyme: it binds to 5'-GGATG-3' but
creates a DSB nine bp away from the binding site. Pro-
teolysis studies of FokI showed that its DNA binding
domain and its DNA cutting (nuclease) domain were se-
parable. Chandrasegaran and his colleagues hypothesi-
zed that if they fused a newDNA binding domain to the
nuclease domain they could create a restriction enzyme
with a novel DNA recognition site [22]. In a series of pa-
pers they fused the nuclease domain first to a homeo-
box DNA binding domain and then to zinc finger DNA
binding domain [23–25].
In both examples they created a protein that would
cut DNA near the site of interaction with the DNA bin-
ding domain. These new proteins were initially called
«chimeric nucleases», later – «zinc finger nucleases»
or ZFNs. The potential of ZFNs was in the nature of the
zinc finger DNA binding domain. The zinc finger DNA
binding domain was first identified by Klug and collea-
gues and the first crystal structure was described by Pa-
bo and colleagues [26, 27].
It has been shown that zinc finger proteins can be
designed to recognize a wide variety of sequences and
suggested that they can be designed to recognize nearly
every sequence [28, 29]. The initial in vitro studies of
ZFNs suggested that a ZFN monomer could cut DNA
but follow-up studies showed that efficient cleavage of
DNA occurred when the nuclease domain is dimerized
[30]. Two consequences of this required dimerization
for cutting were the increasing of specificity and neces-
sity of two ZFNs for each potential target site.
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The collaborative work of Carroll, Chandrasegaran
and their colleagues showed that ZFNs could cut naked
DNA in vitro and could cut DNA and stimulate a form
of homologous recombination, called single-strand
annealing, in Xenopus oocytes [30, 31]. The question
was whether ZFNs could create DSBs in mammalian
genomic DNA and thereby stimulate gene targeting.
To test this hypothesis, Porteus and Baltimore de-
veloped a green fluorescent protein (GFP) based gene
targeting reporter system [32]. In this system, the GFP
gene was mutated by the insertion of recognition sites
for Sce and for a pair of ZFNs. This reporter was inte-
grated as single copy in the genome of a human somatic
cell line (HEK-293 cells). The reporter cell line was
then transfected with a plasmid (repair template) that
would correct the GFPmutation in the integrated repor-
ter and either an expression plasmid for the Sce nuclea-
se or expression plasmids for the ZFNs. They found
that the ZFNs stimulated gene targeting as efficiently
as Sce in this reporter system. Porteus and Baltimore
used ZFNs for which the target binding sites were alrea-
dy known [32].
The next step in the development of the ZFNs was
to show that ZFNs could be prospectively designed to
recognize novel target sites and stimulate gene targe-
ting at those sites [33, 34]. Mutations in the IL2RG are
themost common cause of severe combined immunode-
ficiency (SCID) and exon 5 is a hotspot for disease cau-
sing mutations. They found in K562 cells, a human ery-
throleukemia cell line, that the IL2RG ZFNs could sti-
mulate gene targeting at one allele of the IL2RG gene in
11 % of cells and both alleles of the gene in 6 % of the
cells. Using these ZFNs they showed that they could
first mutate both alleles of the gene in a single step and
then correct both alleles in a second step. Finally, they
showed that the ZFNs could stimulate gene targeting up
to 5 % in primary human T cells. These results showed
that DSBmediated gene targeting by ZFNs could achie-
ve the rates that not only would be useful in an experi-
mental setting but might also be useful as gene therapy
for genetic diseases.
DNA double strand break and rAAV. rAAV and
DSBs can be used to stimulate gene targeting in mam-
malian somatic cells. In fact, combining the two te-
chnologies seems to be synergistic [32, 35]. While the
rate of gene targeting using rAAV is about 10–100 fold
higher than using naked plasmid DNA, the rate of
rAAV mediated gene targeting can be increased by a
further 100 fold by inducing a DSB in the target gene.
ZFN induced gene targeting has a promising feature.
But the technology is still not widely used in mamma-
lian cells because of several unresolved issues.
Mesenchymal stem cells and induced pluripotent
stem cell. Cell therapies using adult stem cells have res-
cued thousands of patients from induced or genetic dis-
orders [36]. Bone marrow (BM)-derived HSC therapy
was first delivered to patients in 1956, following exten-
sive testing in a canine model [37], afterward becoming
a standard clinical procedure, particularly as a treatment
for leukemia and lymphoma [38]. MSCs were first des-
cribed by Friedenstein and colleagues as an adherent
fibroblast-like subset of the BMmicroenvironment cal-
led the «marrow stromal cells», which was capable of
supporting hematopoiesis. Later, these fibroblast like
cells were found to have adult stem cell properties as
they could differentiate into cartilage, bone, fat, and ten-
don [36]. MSCs have been evaluated for regenerative
medicine applications either through direct differentia-
tion into these tissues or indirectly through protein or
cytokine secretion and immune suppression [36, 39–
42]. MSCs have demonstrated systemic migration capa-
bilities after i. v. transplantation, in particular to areas
of hypoxia or tissue damage [43]. Even systemic admi-
nistrations of allogeneic MSCs do not cause any adver-
se effects, in part due to immune modulatory effects
[44, 45]. MSCs have been considered safe as they do
not show tumor formation after transplantation [46] and
have been widely tested and proven efficacious in pre-
clinical and clinical studies for cardiovascular [47] and
neurodegenerative [48] diseases, graft-versus-host disea-
se [44], and autoimmune disease.
MSCs can be efficiently transduced with retroviral
and lentiviral vectors and maintain transgene expres-
sion throughout many passages and lineage-specific
differentiations, with fewer complications caused by vi-
ral integrations [49, 50]. However, the risk of tumor for-
mation due to insertional mutagenesis by viral vector
integrations still raises caution for human clinical appli-
cations [51]. Aging, moreover, significantly reduces the
survival and differentiation potential of BM-MSCs [52].
Human pluripotent stem cells. hESCs have the
potential to differentiate into all types of adult human
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tissues and to grow indefinitely [13]. Since their initial
derivation, hESCs have become promising tools for de-
velopmental biology and regenerative medicine. How-
ever, concerns, related to ethical objections regarding
the use of human embryos for hESC derivation, have
dramatically restricted funding of research on these cells
and, therefore, have set back the development of hESCs
for clinical trials. Because of their allogeneic nature, im-
mune rejection of cells and tissues derived from hESCs
is another potential drawback to their use in transplan-
tation. Immunosuppressive drug regimens, similar to
those used for current human tissue and organ trans-
plant procedures, might lessen the severity of the antici-
pated immune rejection, but at the same time, can also
put the tissue recipient at an increased risk of infections.
This risk can be lessened by application of human leu-
kocyte antigen matched tissue, as is currently being
practiced in organ transplantation, or could be comple-
tely eliminated by the use of the patient’s own tissue. The
latter possibility can now be achieved by application of
autologous iPSCs, the patient's own somatic cells, and
reprogramming them to become pluripotent cells [53].
Following groundbreaking work by Yamanaka and
colleagues demonstrating that mouse fibroblasts could
be converted into iPSCs by retroviral delivery of the
genes of four transcription factors (Oct4, Sox2, Klf4,
and Myc), other groups reported that terminally diffe-
rentiated human somatic cells could be reprogrammed
into a pluripotent state using retroviral or lentiviral vec-
tors transferring the genes of the same four transcrip-
tion factors. In many ways, iPSCs are similar to hESCs,
in their morphology, gene expression, in vitro differen-
tiation potential, and teratoma formation. However, in-
herent «epigenetic memory» of the initial cells may in-
fluence specific differentiation and in vivo functiona-
lity of tissues derived from such reprogrammed cells.
More research in this area is needed to determine the
best starting somatic cell for iPSC generation that al-
lows reproducible differentiation into different types of
functional tissues for human clinical applications. iPSCs
hold great potential for regenerative medicine, as can
already be demonstrated in mouse models of Parkin-
son’s disease [54] and sickle cell anemia [55]. Disease
specific iPSC lines for modeling «diseases in a dish»,
screening new drug compounds, and developing new
therapies have been used successfully [56–58]. How-
ever, clinical applications of iPSCs have been criticized
because of the possibility to form tumors by integrated
oncogenes, c-Myc in particular [59], by insertional mu-
tagenesis that has the potential to cause cancers [60] or
disrupt tumor suppressor genes [51], and recently, be-
cause of epigenetic memories and genomic aberrations
in the reprogrammed cells [61]. Therefore, to manufac-
ture iPSCs for clinical applications, several safety mea-
sures need to be taken.
As BM-MSCs can easily be harvested from adult
sources and cultured in vitro, many preclinical and clini-
cal studies have used BM-MSCs [36]. Although easy
access to BM-MSCs is recognized as a great advantage,
extended in vitro culture reduces the differentiation po-
tential of MSCs, which limits their therapeutic efficacy
[62]. To overcome this shortfall, MSCs derived from
iPSCsmay, therefore, be considered for human cell and
gene therapy applications as iPSCs have the potential
to be expanded indefinitely without senescence (Figu-
re). Several laboratories have already shown thatMSCs
derived from hESC have the same in vitro and in vivo
characteristics as MSCs derived from adult sources
[63, 64]. It is reported that hESC derived MSCs were
karyotipically stable, had the same cell surface pheno-
type as MSCs isolated from adult BM, and could home
similarly to areas of hypoxic injury in a hindlimb is-
chemia model [64]. It was shown that MSCs derived
from human iPSCs can be generated in clonal expan-
sion cultures and can be differentiated into osteoblasts,
adipocytes, and chondrocytes and promote vascular
and muscle regeneration. The authors also described a
greater regenerative potential of MSCs derived from
iPSCs, whichmay be attributed to superior survival and
engraftment after transplantation, because of higher te-
lomerase activity and less senescence as compared to
BM-MSCs [65].
In these studies, iPSC or hESC derived MSCs were
comparable to BM-MSCs in surface marker expression,
differentiation potential, and in vivo regenerative poten-
tial in the mouse hind limb ischemia model. Future stu-
dies should examine the efficiency of MSC derivation
based on different clinically relevant protocols or cell
sources, with term follow-up of in vivo safety and ef-
ficacy studies.
GeneticallymodifiedMSCsmay also serve as cellu-
lar therapeutics sinceMSCs can be used as targeted drug
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delivery vehicles [42]. Previous direct injection of the
VEGF protein and gene therapy vectors carrying VEGF
showed promise in Phase I–II clinical trials but did not
achieve significance in Phase III trials [66]. MSCs,
however, migrate to ischemic areas, remain there for an
extended period of time, as has been demonstrated in
preclinical animal models [42, 67], and could continu-
ously deliver VEGF. This could become a cellular thera-
py using highly tested allogeneic, transduced MSCs.
These MSCs could be generated from iPSCs that were
created in an integration free system and transduced
with a VEGF vector; these could be selected for safe har-
bor integrations of the transgene to exclude the possibi-
lity of tumor formation due to insertional mutagenesis.
Regulatory issues. The US Food and Drug Admi-
nistration (FDA) regulates the clinical application of
cell and gene therapy. The final cellular product admi-
nistered into a patient must meet important safety and
several criteria, such as identity, purity, potency, clini-
cal safety, and efficacy [68]. Besides criteria that all cel-
lular products must meet, such as sterility, viability and
freedom from endotoxin, particular concerns for stem
cells are characterization of the product, including in vit-
ro and in vivo potency, freedom from cell differentia-
tion to undesired cell types, in vivo cell migration/traf-
ficking to non target site, potential uncontrolled cell
proliferation or tumorigenicity, immunogenicity, graft-
versus-host effects, interactions with devices, other tis-
sues or drugs in vivo. For gene-modified cells the chal-
lenges are potential uncontrolled biological activity of
the transgene, alteration of expression of the non-trans-
genes, and insertional mutagenesis.
Generation of clinically appropriate iPSCs. At
this point, iPSCs are not yet clinically applicable, while
being under intensive development. One of the most
important goals for the manufacturing of a safe stem
cell product is the prevention of tumor formation after
transplantation. Tumors could be generated in iPSC me-
diated clinical applications by insertional mutagenesis
caused by transgenes used for reprogramming [69], by
enhancer effects caused by particular viral sequences
found in retroviral or lentiviral vectors [60], and by dis-
ruptions of essential genes caused by integrated vector
cassettes [51]. Teratomas could be caused by undiffe-
rentiated cells contaminating the differentiated final
product. Integrated c-Myc delivered by a retroviral vec-
tor has been shown to cause tumor formation in 40% of
mice due to the reactivation of silenced genes [69]. In
adult stem cell therapies, genetically modified cells can
carry the risk of tumor generation. An HSC gene the-
rapy clinical trial to treat X-linked severe combined im-
munodeficiency disease (X-SCID) using a retrovirus
caused 4 out of 11 children to develop leukemia [60, 70].
Another concern may be cell transformation caused by
gene disruption. An HSC therapy paper claimed that
integrated lentiviral vector had disrupted a tumor sup-
pressor gene leading to the premature termination of en-
dogenous genes that could cause tumor formation [51].
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A. Skin biopsy
F. Translplantation
E. Differentiation and expansion of
genetically modified MSCs
D. Selection of clone
with safe harbor
integration
C. Gene correction
of transduction
B. Reprogramming
to iPSC
Schematic diagram of iPSC gene therapy: A –
patients fibroblasts from skin biopsy are cul-
tured; B – patient-specific cells can be repro-
grammed by viral delivery of induction fac-
tors or nonintegrating methods; C – gene cor-
rection can be accomplished by vector-media-
ted gene transfer or gene exchange by homolo-
gous recombination; D – gene-corrected iPSCs
can be screened by sequencing to find a clone
with proper gene correction or integration in-
to a safe harbor site; E – gene-modified iPSCs
can be differentiated into MSCs and expan-
ded; F – MSCs with gene integration into the
controlled site can be tested, expanded, and
purified in a good manufacturing practice fa-
cility and could then be transplanted to the pa-
tient, following appropriate clearance by all
regulatory agencies
This effect could bemonitored by in vitro cell immorta-
lization assays and serial transplantation experiments
in vivo [46, 71].
MSCs derived from iPSCs with safe harbor thera-
peutic gene integrations, or gene corrections by homo-
logous recombination, could significantly reduce the
chance of tumor formation as these cells can be scre-
ened to avoid gene disruptions or oncogene activation.
iPSC colonies can be specifically selected for proper
gene insertion, can be highly tested, and then expanded
at large scale for master cell bank generation prior to
directed differentiation to MSCs or other lineages. Ge-
ne-modified iPSC derivedMSCs could be used for safe
administration of a therapeutic gene product to specific
sites of injury or inflammation, as MSCs are known to
migrate to such areas in vivo [42, 48, 64].
The improvement of reprogramming technology for
safe iPSC derivation is important for human therapeu-
tic applications, and permanent transgene integrations
for reprogramming should be avoided. Recent papers
have described many approaches to accomplish this,
such as adenoviral vector transductions, DNA plasmid
vector transfections, Cre-LoxP excision of reprogram-
ming vector cassettes transferred by a lentiviral vector,
transposons, episomal Epstein-Barr virus, mRNA trans-
fections, and protein transfections [72]. Additionally,
small molecule-mediated reprogramming has become
interesting for clinically relevant iPSC generation [73].
Epigenetic memory and genetic abnormalities.
Another important concern for cellular therapies is whe-
ther the transplanted cells may become unstable or could
be transformed into tumors. A number of studies have
demonstrated that iPSCs contain abnormalities at the
genetic and epigenetic level and that these defects are
often related to oncogenic pathways [61, 74–76]. The
epigenetic memory of iPSCs with its incomplete epi-
genetic reorganization and skewed differentiation po-
tential also raises the question whether such cells may
actually be suitable for therapeutic applications.
Cell culture conditions. Phase I clinical trial apply-
ing hESC-derived neuronal tissues for the treatment of
spinal cord injury has been recently approved by the
FDA. The laboratory manufacturing an iPSC or hESC
derived cellular product should be in compliance with
FDA safety regulations, otherwise the product will not
be able to progress to Phase II or III clinical trials, and
will have to be rederived. Additionally, to generate a
safe and clinically acceptable iPSC-derived product,
xeno-free cell culture conditions should be used to mini-
mize the risk of transmitting disease or causing human
immune reactions [68].
Reliability of iPSC differentiation. Several clini-
cally applicable reprogramming technologies are avai-
lable but still the consistency of iPSC derived products
is a concern. Single cell clonal expansion of human
iPSCs has shown low survival rates compared to mouse
counterparts [77], therefore, developing reliable and
reproducible standard protocols to differentiate and se-
lect iPSC-derived cellular products is a pressing issue.
There are indications that due to the epigenetic me-
mory or incomplete reprogramming, some iPSC lines
favor specific differentiation pathways [78]. Differen-
tiated cells can be thought of as a heterogeneous popu-
lation of desired, differentiated cells mixed with undesi-
red, undifferentiated cells, in spite of the application of
efficient direct-differentiation methods [79]. To elimi-
nate undifferentiated PSCs from the population of dif-
ferentiated cells, several techniques have to be asses-
sed. Cell sorting using a clinical grade flow cytometric
cell sorter under specific conditions can be one of the
solutions. Introduction of a suicide gene only expres-
sed in undifferentiated cells and antibodies directed
against stem cell-specific surface markers could be used
to selectively kill or capture and remove undifferen-
tiated PSCs.
Conclusions. The Food and Drug Administration
(FDA) has not yet approved any human gene therapy
product for sale. Current gene therapy is experimental
and has not proven very successful in clinical trials.
Before gene therapy can become a permanent cure
for any condition, the therapeutic DNA introduced into
target cells must remain functional and the cells con-
taining the therapeutic DNA must be long-lived and
stable. The problems with integrating therapeutic DNA
into the genome and the rapidly dividing nature of ma-
ny cells prevent gene therapy from achieving any long-
term benefits. Patients will have to undergo multiple
rounds of gene therapy.
The risk of stimulating the immune system in a way
that reduces gene therapy effectiveness is always a po-
tential item. Furthermore, the immune system’s enhan-
ced response to invaders it has seen before makes it dif-
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ficult for gene therapy to be repeated in patients. Viru-
ses as the carrier of choice in most gene therapy studies
pose a variety of potential problems to the patient like
toxicity, immune and inflammatory responses, gene
control and targeting issues. In addition, there is always
the fear that the viral vector, once inside the patient, may
recover its ability to cause disease.
iPSCs derived from patient’s ownMSCs have won
the laurels for stem cell-based gene therapy. iPSCs- ba-
sed therapies are under trial nowadays. It is aimed at ge-
nerating stable and fully functional stem cell lines accor-
ding to particular patient’s need. rAAV-ZFN technolo-
gy dependant homologous recombination is extensive-
ly used as gene targeting and gene correction tool. Stem
cell-based therapies hold great potential to become the
future regenerative medicine. Research is actively going
on in this respect.
Ç. Íàç³ð, Ñ. ²ðøàä
Ãåííà òåðàï³ÿ, çàñíîâàíà íà ñòîâáóðîâèõ êë³òèíàõ
Ðåçþìå
Ñòîâáóðîâ³ êë³òèíè ìàþòü âåëè÷åçíèé ïîòåíö³àë äëÿ ðåãåíåðà-
òèâíî¿ ìåäèöèíè. Ïðîòÿãîì äåñÿòèë³òü áóëî äîâåäåíî áåçïåêó ³
åôåêòèâí³ñòü òåðàï³¿ íà îñíîâ³ HSC, ó òîé ÷àñ ÿê âèêîðèñòàííÿ
MSC, îáìåæåíå ñòðîêàìè çáåð³ãàííÿ êë³òèí òà äåÿêèìè ³íøèìè
ïðè÷èíàìè, ëèøå â îêðåìèõ åêñïåðèìåíòàõ äàâàëî ïîçèòèâí³ íà-
ñë³äêè ç êîðîòêî÷àñíîþ ä³ºþ, ÿê³ ïîòðåáóþòü ïîäàëüøîãî âè-
â÷åííÿ. Íåçâàæàþ÷è íà òå, ùî ²ÏÑÊ çàëèøàþòüñÿ îñíîâíèì äæå-
ðåëîì ïðè òåðàï³¿ ñòîâáóðîâèìè êë³òèíàìè, ÿê ³ ðàí³øå, ³ñíóþòü
ñåðéîçí³ ïèòàííÿ á³îáåçïåêè, ÿê³ ïîòð³áíî âðàõîâóâàòè îñîáëèâî
â ðàç³ êë³òèí, ùî ïðîäàþòüñÿ äëÿ êë³í³÷íèõ âèïðîáóâàíü. Òèì íå
ìåíø, íàéïåðñïåêòèâí³øèìè äëÿ ðåãåíåðàòèâíî¿ ìåäèöèíè ìàé-
áóòíüîãî º ë³í³¿ ñòîâáóðîâèõ êë³òèí, ñòâîðåí³ äëÿ êîíêðåòíîãî
ïàö³ºíòà, à òàêîæ êîðèãóâàííÿ ãîìîëîã³÷íèõ ãåí³â ³ âáóäîâóâàííÿ
òðàíñãåíà â ïåâíå ì³ñöå â ãåíîì³ äëÿ ïîäàëüøî¿ åêñïðåñ³¿ ³ äèôå-
ðåíö³þâàííÿ. Êð³ì òîãî, ðîçâèòîê ðåêîìá³íàíòíî¿ àäåíîâ³ðóñíî¿
òåõíîëîã³¿ (rAAV) ³ âèêîðèñòàííÿ íóêëåàçè öèíêîâîãî ïàëüöÿ (ZFN)
äîçâîëÿº ââàæàòè ãîìîëîã³÷íó ðåêîìá³íàö³þ íàéêðàùèì ³íñòðó-
ìåíòîì äëÿ ãåííî¿ òåðàï³¿, çàñíîâàíî¿ íà ñòîâáóðîâèõ êë³òèíàõ.
Êëþ÷îâ³ ñëîâà: äîðîñë³ ñòîâáóðîâ³ êë³òèíè, ÌÑÊ, ²ÏÑÊ, ZFN,
rAAV, êîðåêö³ÿ ãîìîëîã³÷íèõ ãåí³â, ðåãåíåðàòèâíà ìåäèöèíà.
Ç. Íàçèð, Ñ. Èðøàä
Ãåííàÿ òåðàïèÿ, îñíîâàíààÿ íà ñòâîëîâûõ êëåòêàõ
Ðåçþìå
Ñòâîëîâûå êëåòêè îáëàäàþò îãðîìíûì ïîòåíöèàëîì äëÿ ðåãåíå-
ðàòèâíîé ìåäèöèíû. Íà ïðîòÿæåíèè äåñÿòèëåòèé áûëè äîêàçà-
íû áåçîïàñíîñòü è ýôôåêòèâíîñòü òåðàïèè íà îñíîâå HSC, â òî
âðåìÿ êàê èñïîëüçîâàíèå MSC, îãðàíè÷åííîå ñðîêàìè õðàíåíèÿ
êëåòîê è íåêîòîðûìè äðóãèìè ïðè÷èíàìè, ëèøü â îòäåëüíûõ ýêñ-
ïåðèìåíòàõ äàâàëî ïîëîæèòåëüíûå ðåçóëüòàòû ñ êðàòêîâðåìåí-
íûì äåéñòâèåì, ÷òîòðåáóåò äàëüíåéøåãî èçó÷åíèÿ. Íåñìîòðÿ íà
òî, ÷òî íà ÈÏÑÊ âîçëàãàþò áîëüøèå íàäåæäû ïðè òåðàïèè
ñòâîëîâûìè êëåòêàìè, ïî-ïðåæíåìó ñóùåñòâóþò ñåðüåçíûå
âîïðîñû áèîáåçîïàñíîñòè, êîòîðûå íóæíî ó÷èòûâàòü îñîáåííî
â ñëó÷àå êëåòîê, ïðîäàþùèõñÿ äëÿ êëèíè÷åñêèõ èñïûòàíèé. Òåì
íå ìåíåå, íàèáîëüøèì ïîòåíöèàëîì äëÿ ðåãåíåðàòèâíîé ìåäèöè-
íû áóäóùåãî îáëàäàþò ëèíèè ñòâîëîâûõ êëåòîê, ñîçäàííûå äëÿ
êîíêðåòíîãî ïàöèåíòà, à òàêæå êîððåëÿöèÿ ãîìîëîãè÷íûõ ãåíîâ
è âñòðàèâàíèå òðàíñãåíà â îïðåäåëåííîå ìåñòî â ãåíîìå äëÿ äàëü-
íåéøåé ýêñïðåññèè è äèôôåðåíöèàöèè. Êðîìå òîãî, ðàçâèòèå ðå-
êîìáèíàíòíîé àäåíîâèðóñíîé òåõíîëîãèè (rAAV) è èñïîëüçîâàíèÿ
íóêëåàçû öèíêîâîãî ïàëüöà (ZFN) ïîçâîëÿåò ñ÷èòàòü ãîìîëîãè÷-
íóþ ðåêîìáèíàöèþ íàèëó÷øèì èíñòðóìåíòîì äëÿ ãåííîé òåðà-
ïèè, îñíîâàííîé íà ñòâîëîâûõ êëåòêàõ.
Êëþ÷åâûå ñëîâà: âçðîñëûå ñòâîëîâûå êëåòêè,ÌÑÊ, ÈÏÑÊ, ZFN,
rAAV, êîððåêöèÿ ãîìîëîãè÷íûõ ãåíîâ, ðåãåíåðàòèâíàÿ ìåäèöèíà.
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